Interferon Beta-1a Plus Remdesivir Did Not Benefit Hospitalized Adults With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2021 Oct 18;[EPub Ahead of Print], AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, CR Wolfe, GM Ruiz-Palacios, S Kline, J Regalado Pineda, AF Luetkemeyer, MS Harkins, PEH Jackson, NM Iovine, VF Tapson, MD Oh, JA Whitaker, RA Mularski, CI Paules, D Ince, J Takasaki, DA Sweeney, U Sandkovsky, DL Wyles, E Hohmann, KA Grimes, R Grossberg, M Laguio-Vila, AA Lambert, D Lopez de Castilla, E Kim, L Larson, CR Wan, JJ Traenkner, PO Ponce, JE Patterson, PA Goepfert, TA Sofarelli, S Mocherla, ER Ko, A Ponce de Leon, SB Doernberg, RL Atmar, RC Maves, F Dangond, J Ferreira, M Green, M Makowski, T Bonnett, T Beresnev, V Ghazaryan, W Dempsey, SU Nayak, L Dodd, KM Tomashek, JH BeigelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.